Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 5 Lung Neoplasms 3 Colorectal Neoplasms 3 Small Cell Lung Carcinoma 1 Neoplasm Metastasis 1 NSCLC 1 Brain Neoplasms 1

Interventions

Pemetrexed 14 Carboplatin 13 osimertinib 10 Drug Therapy 9 aflutinib 8 Gefitinib 7 Radiotherapy 6 Docetaxel 6 Cisplatin 6 anlotinib 5 Radiosurgery 5 Paclitaxel 5 pembrolizumab 4 Vinorelbine 4 Gemcitabine 4 tislelizumab 3 icotinib 3 apatinib 3 HM781-36B 3 Erlotinib Hydrochloride 3 toripalimab 2 spartalizumab 2 rezivertinib 2 camrelizumab 2 Tyrosine Kinase Inhibitors 2 Thalidomide 2 Surgical Procedures, Operative 2 S 1 (combination) 2 Platinum 2 Immune Checkpoint Inhibitors 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × NSCLC × JDQ443 × Clear all

NCT05714891 2026-02-12

Neoadjuvant Platform Trial in Non-Small Cell Lung Cancer

Canadian Cancer Trials Group

Phase 2 Active not recruiting

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡